The UK aesthetic medical market has spent the last several years scaling rapidly inside a regulatory framework that has consistently lagged the procedures being offered. That gap is closing. Section 180 of the Health and Care Act 2022 gave the Government the legislative basis to introduce a licensing scheme for non-surgical cosmetic procedures in England, the Department of Health and Social Care (DHSC) has consulted on what such a scheme would look like, and the consultation outcome was published in August 2025. A further consultation is planned for early 2026.
For clinic operators, the question is no longer whether tiered licensing is coming. It is how to be ready when it arrives, and how to finance the practical changes (training, equipment, fit-out, indemnity) without distorting the rest of the business in the meantime.
What the consultation has indicated
The proposed direction is a Red, Amber, Green (RAG) tiered system, with each tier carrying different requirements:
- Red, the high-risk tier, would restrict procedures (for example certain breast, buttock, and intimate-area filler treatments, and procedures involving threads) to qualified healthcare professionals working in CQC-registered settings.
- Amber, the medium-risk tier, would cover injectable toxins, dermal fillers, intravenous infusions, ablative lasers, chemical peels, and similar treatments. Non-healthcare practitioners would be able to perform these only under defined oversight from a named regulated healthcare professional.
- Green, the lower-risk tier, would cover treatments such as microneedling and similar shallow-penetration procedures, with licensing required but supervision not.
Local authorities are proposed as the licensing and enforcement body, working alongside environmental health and trading standards. A minimum age of 18 has been proposed across all licensed procedures. The Government’s published consultation response and the House of Commons Library briefing both set out the detail. DHSC consultation response and House of Commons Library briefing are the authoritative sources.
It is important to note what the position is not. As of the publication of the consultation response in August 2025, the licensing scheme is not yet in force. The Government has set out an intention to proceed, with a further consultation in early 2026 on the design detail. Operators planning capital expenditure now are doing so against a clearly signalled direction of travel rather than against a finalised statutory regime.
What the market actually looks like
Recent academic mapping of the UK aesthetic medicine industry, published in 2025, identified just under 20,000 practitioners working across roughly 5,500 clinics, a substantial increase on equivalent data from two years earlier. The composition of the practitioner base is also changing, with a growing share of non-medical aestheticians alongside doctors, nurses, and dentists. That growth, combined with the proposed tiered scheme, sets up exactly the kind of consolidation pressure that has played out in other regulated healthcare-adjacent sectors. The peer-reviewed mapping work is available through the National Library of Medicine. PMC mapping study.
The capital implications for clinic operators
Three distinct capital lines are typically pressured by a regulatory transition of this kind:
- Fit-out and clinical environment. Treatment rooms suitable for Amber-tier procedures performed under healthcare oversight have different requirements from rooms used for lower-tier work. Sites that have invested in flexible space tend to age into the new regime more cleanly than sites that have not.
- Equipment. Lasers, energy-based devices, and IV-related equipment carry meaningful price tags and longer working lives than most clinic operators want to fund out of trading cashflow. These are exactly the assets that benefit from hire-purchase or lease structures matched to working life.
- Working capital. Training programmes, supervisor relationships for non-healthcare practitioners performing Amber-tier work, indemnity premiums, and licensing fees all hit the operating account before any uplift in pricing follows.
A clinic that funds all three from one overdraft or one term loan tends to find itself reorganising the same facility three times. Clinics that separate the equipment piece into asset finance, the fit-out into multi-site or growth finance, and the working capital piece into a properly sized line tend to navigate transitions like this with much less stress on the operating model.
Where LMC fits in
Last Mile Capital provides clinic, fit-out, and equipment finance for aesthetic medical operators across the UK, with credit work that respects the regulatory context the sector is moving into rather than pretending it is a generic small-business case. More on the sector approach is at our aesthetic medical sector page, and the customer-facing product set is at for customers.
The licensing scheme is not finalised. The direction of travel is. Capital structures put in place over the next twelve months will determine which operators are still independent in three years’ time.
Image: “Modern medical examination room” by Shixart1985, licensed under CC BY 2.0.
